Skip to main content
. 2022 Oct 26;4(3):100423. doi: 10.1016/j.jtocrr.2022.100423

Figure 2.

Figure 2

Antitumor activity of vidutolimod and atezolizumab with and without RT in NSCLC over time. Percent change from baseline in SLD of target lesions over time in part A (A) and part B (B). In parts A and B, two patients and four patients were excluded from the plot owing to missing scans or incomplete postbaseline imaging, respectively. PD, progressive disease; RECIST v1.1, Response Evaluation Criteria in Solid Tumors version 1.1; RT, radiation therapy; SLD, sum of longest diameter.